Profession Notes

Breast Cancer Consensus Conference The National Institutes of Health's Office of Medical Applications of Research (OMAR) will hold a consensus conference Nov. 1-3, 2000, on the NIH campus to discuss adjuvant therapies for breast cancer. The first NIH consensus conference on breast cancer therapy in 10 years, it will address the ins and outs of adjuvant radiation, chemotherapy, and hormonal therapy, as well as promising future directions for related research. As with all consensus conferences, he

Written byEugene Russo
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Breast Cancer Consensus Conference

The National Institutes of Health's Office of Medical Applications of Research (OMAR) will hold a consensus conference Nov. 1-3, 2000, on the NIH campus to discuss adjuvant therapies for breast cancer. The first NIH consensus conference on breast cancer therapy in 10 years, it will address the ins and outs of adjuvant radiation, chemotherapy, and hormonal therapy, as well as promising future directions for related research. As with all consensus conferences, health professionals, researchers, patient advocates, and other members of the public are invited to hear an independent panel of scientists present their findings. Based on the presentations and on public comments, the panel drafts a consensus statement meant to advance the understanding of the issues addressed. To register for the breast cancer conference, send an E-mail to breastcancer@prospectassoc.com or see the NIH Consensus Development Program Web site at odp.od.nih.gov/consensus.

--Eugene Russo

Computational Biology Fellowship

The ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies